⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17703506 | 0.81 | — | — | |
| SCHEMBL10201411 | 0.81 | — | — | |
| SCHEMBL30527628 | 0.81 | — | — | |
| SCHEMBL14568136 | 0.81 | — | — | |
| SCHEMBL30774846 | 0.81 | — | — | |
| SCHEMBL25309315 | 0.81 | — | — | |
| SCHEMBL11839854 | 0.81 | — | — | |
| SCHEMBL19151430 | 0.75 | NOX1 (0.33) | — | |
| SCHEMBL16248188 | 0.75 | GABRA1 (0.45) | — | |
| SCHEMBL15334246 | 0.75 | AKR1C3 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118930480-A | Synthesis method of 2- (3, 5-dibromopyridine-4-yloxy) ethylamine dihydrochloride | 南通敏言生物医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| EP-4624464-A1 | PYRIDINE POLYCYCLIC COMPOUND INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| CN-118930480-A | Synthesis method of 2- (3, 5-dibromopyridine-4-yloxy) ethylamine dihydrochloride | 南通敏言生物医药科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118930480-A | Synthesis method of 2- (3, 5-dibromopyridine-4-yloxy) ethylamine dihydrochloride | 南通敏言生物医药科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024109885-A1 | PYRIDINE POLYCYCLIC COMPOUND INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-110483383-B | Preparation method of pyridine derivative | 新发药业有限公司 | 2021-04-16 | — | — | CN | disclosed |
| EP-2970248-B1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED INC (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
| CN-104185627-B | Pyridone Derivatives | 第三共株式会社 | 2018-01-12 | — | — | CN | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
| WO-2007033196-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |